Background: Patients with end-stage renal disease are at increased risk for sudden cardiac death, although the utility of implantable cardioverter-defibrillators (ICDs) in these patients is unknown.
Objectives: The purpose of this study was to evaluate whether end-stage renal disease is an independent risk factor for appropriate ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF) and to compare the long-term survival of ICD recipients with and without end-stage renal disease.
Methods: A retrospective cohort study was performed on ICD recipients at a single center. The primary endpoint was first appropriate ICD therapy for VT/VF. The secondary endpoint was survival.
Results: The study included 585 patients, 19 (3.2%) of whom had end-stage renal disease prior to device implantation. Average follow-up time was 2.2 +/- 2.4 years, during which time 156 patients (26.7%) received appropriate ICD therapy. End-stage renal disease was strongly associated with appropriate ICD therapy (hazard ratio 2.30, 95% confidence interval 1.17-4.54) and remained a significant predictor following adjustment for implant indication, ejection fraction, diabetes, hypertension, and beta-blocker use. Survival was significantly shorter in the end-stage renal disease patients, with a median survival time of 3.2 +/- 0.6 (SEM) years in the dialysis cohort and 7.4 +/- 0.5 (SEM) years in those without end-stage renal disease (log rank P = .009). The majority of deaths in the end-stage renal disease cohort were due to non-device-related infection.
Conclusion: In this cohort, end-stage renal disease was the single greatest predictor of ICD therapies for VT/VF. The survival rate was significantly shorter than that of ICD recipients without end-stage renal disease, suggesting that comorbidities in end-stage renal disease patients meeting current implant indications may reduce the survival benefit of ICD placement in this population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hrthm.2006.06.013 | DOI Listing |
J Coll Physicians Surg Pak
January 2025
Department of Anaesthesiology and Reanimation, Division of Intensive Care Medicine, Izmir Tepecik Training and Research Hospital, Izmir, Turkiye.
Objective: To evaluate the association of serum albumin levels with short-term mortality in ICU patients, including ICU and 28-day mortality.
Study Design: Observational study. Place and Duration of the Study: Intensive Care Unit, Izmir Tepecik Training and Research Hospital, Izmir, Turkiye, from January to July 2023.
J Am Board Fam Med
January 2025
From the UPMC St. Margaret Family Medicine Residency Program, Pittsburgh, PA (WF, YG).
Use the new eGFR equation (estimated glomerular filtration rate equation that incorporates both serum creatinine and serum cystatin C levels) to estimate the GFR for both Black and non-Black individuals because the equation has improved accuracy, minimizes differences in eGFR between race groups, and more accurately reflects chronic kidney disease (CKD) prognosis while eliminating the use of race in GFR estimating equations.
View Article and Find Full Text PDFKidney360
January 2025
Center for Cardiac Arrest Prevention, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Health System, Los Angeles, CA, United States.
Background: Individuals with end-stage renal disease may be at increased risk of sudden cardiac arrest (SCA) associated with dialysis therapy. However, community-based studies with comprehensive adjudication of SCA are lacking.
Methods: We conducted a community-based study using a case-case study design in a US population of ≈1 million.
Kidney Med
December 2024
Department of Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA.
Rationale & Objective: Nearly half of kidney transplant recipients develop allograft failure within 10 years of transplantation and experience high mortality, significant symptom burden, and complex communication challenges. These patients may benefit from palliative care, but palliative care is infrequently provided in this population. This study explores palliative care perceptions and needs among patients with poorly functioning and declining kidney allografts.
View Article and Find Full Text PDFJACC Case Rep
January 2025
Division of Cardiothoracic Surgery, Department of Surgery, Virginia Commonwealth University, Richmond, Virginia, USA.
Extracavitary cardiac calcific amorphous tumors/masses are extremely rare. We present a case report of a 62-year-old man with end-stage renal disease who presented with extracavitary cardiac calcific amorphous tumors/masses compressing the biventricular outflow tracts, resulting in hemodynamic compromise and progressive limitation of activities. The patient was successfully treated with surgery, with complete resolution of symptoms and markedly improved quality of life.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!